Latest Research And Development News

Page 41 of 82
Alexium International Group Limited posted a 42.2% increase in net loss for FY2025, with revenues down 33.4% due to a soft US mattress market. Despite financial setbacks, the company advanced key technologies and announced leadership changes that could fuel future growth.
Victor Sage
Victor Sage
28 Aug 2025
FortifAI Limited reported a 15% decline in game revenue to $4.3 million for FY2025 but achieved a significant 72% reduction in net loss to $1.99 million, supported by operational cost cuts and a $3.6 million capital raise.
Sophie Babbage
Sophie Babbage
28 Aug 2025
NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.
Ada Torres
Ada Torres
28 Aug 2025
Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.
Ada Torres
Ada Torres
28 Aug 2025
PYC Therapeutics reported a 14.5% rise in income to AUD 26.17 million for FY2025 alongside a 33.3% increase in net loss, while increasing its stake in Vision Pharma to 97.1%. The auditor flagged material uncertainty over the company’s ability to continue as a going concern.
Ada Torres
Ada Torres
28 Aug 2025
Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.
Victor Sage
Victor Sage
28 Aug 2025
Identitii Limited reported a modest 4% revenue increase to $777,542 for FY25, yet its net loss expanded by 8% to $3.82 million, driven by lower investment gains. The company strengthened its cash position through successful capital raising and ongoing cost reductions.
Sophie Babbage
Sophie Babbage
28 Aug 2025
Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.
Ada Torres
Ada Torres
28 Aug 2025
Archer Materials has made notable advances in its quantum computing and biosensor technologies during FY25, alongside leadership changes and a widened net loss. The company’s progress signals growing momentum in its commercialisation efforts.
Sophie Babbage
Sophie Babbage
28 Aug 2025
Syntara Limited reported a significantly reduced loss for FY2025, driven by clinical progress and capital raises, while advancing its lead drug amsulostat with FDA Fast Track designation. The company also navigates ongoing payment disputes following the sale of its mannitol respiratory business.
Ada Torres
Ada Torres
28 Aug 2025
Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.
Ada Torres
Ada Torres
28 Aug 2025
Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.
Ada Torres
Ada Torres
28 Aug 2025